Avalon Pharmaأفالون فارما
- Price
- 61.70 SAR
- Fair value
- 26.43 SAR
- Discount to fair value
- −133%
- Mkt cap
- 2.16B
- P/E
- 22.3×
- P/B
- 5.19×
- EV
- 2.19B
- Div yield
- 2.17%
- ROE
- 23.3%
- Net margin
- 21.1%
Current price61.7SAR
Fair value (est., median)26.43SAR
UndervaluedFair valueOvervalued
+133.4% above fair valueWould need to fall ~57.2% to reach fair value.
Median ofDCF 34.14DDM 18.82Graham 26.43Residual Income 30.05Earnings Power 24.86
Health Check
61.2
Overall / 100
Good (66+)Caution (40–65)Risk (<40)
Rewards
- Strong return on equity (23.3%).
- Healthy balance sheet.
- Attractive, covered dividend (2.17%).
- Above-average growth expected.
Risks
- Trades 133.5% above estimated fair value.
- Low fair-value confidence — methods disagree or data is thin.
Scores are computed automatically from the real financial statements (Value from fair value; the rest from growth, profitability, balance sheet and dividends). A decision aid, not investment advice.
Price, corporate actions & news
Demo series
D — DividendS — Split▲ good · ▼ bad newstap a marker for detailsDemo series
Growth & profitability
Revenue, net income and margin.
RevenueNet incomeNet margin %tap a bar for figures
Key figures
Covers 3 years · FY2023–FY2025
| Metric | FY'23 | FY'24 | FY'25 | TTM'26 |
|---|---|---|---|---|
| Revenue | 338.44M | 394.00M | 460.48M | — |
| Net Income | 65.83M | 79.85M | 97.01M | 104.51M |
| Net Margin | 19.5% | 20.3% | 21.1% | — |
| Operating Cash Flow | 92.66M | 33.08M | 88.54M | — |
| OCF Margin | 27.4% | 8.4% | 19.2% | — |
| Capital Expenditure | 30.97M | 20.95M | 34.42M | — |
| Free Cash Flow | 61.69M | 12.12M | 54.12M | — |
| FCF Margin | 18.2% | 3.1% | 11.8% | — |
| FCF Conversion | 93.7% | 15.2% | 55.8% | — |
| EPS (Diluted) | 1.88/sh | 2.28/sh | 2.77/sh | 2.99/sh |
| Dividend / Share | 1.03/sh | 0.43/sh | 1.34/sh | — |
Dividend return (if you buy today)if you buy today
Dividend yield2.18%
Dividend / share1.34
If you invest
Shares (≈)162
Est. annual income217.45
At this rate, dividends alone return your capital in ~46.0 years.
Dividend history
Dividend / share & historical yield (SAR).
Dividend / share yield %tap a bar for figures
Quarterly dividends & yield
Per-share dividends by quarter, full-year total, and yield on the year's average price · SAR
| Year | Q1 | Q2 | Q3 | Q4 | Full year | Yield (avg) |
|---|---|---|---|---|---|---|
| 2026 | — | — | — | — | — | — |
| 2025 | — | — | — | — | 1.34 | — |
| 2024 | — | — | — | — | 0.43 | — |
| 2023 | — | — | — | — | 1.03 | — |
Valuation breakdown
Fair value = median of the applicable methods (DCF، DDM، Graham، Residual Income، Earnings Power).
Each method below is a different lens on the same company — no single method dominates the result.
Discounted Cash Flow
Values the company from the future cash it's expected to generate. · Tap to adjust assumptions
34.14
Dividend Discount Model
Values the share from the dividends it's expected to keep paying. · Tap to adjust assumptions
18.82
Graham Number
A conservative benchmark built from earnings and book value. · Tap to adjust assumptions
26.43
Residual Income (justified P/B)
Values the profit the company earns above the cost of its equity. · Tap to adjust assumptions
30.05
Earnings Power Value
Values today's earning power as-is, assuming no growth. · Tap to adjust assumptions
24.86
DCF only is anchored on FY2025 — the latest year with positive cash flow that supports a value. The other methods (DDM, Graham, RIM, EPV) use current / normalized figures.
Fair Value (median)26.43
▸ Show assumptions▾ Assumptions
- Effective discount rate
- 10.35%
- CAPM cost of equity
- 10.50%
- Risk-free rate
- 4.50%
- Equity risk premium
- 6.00%
- DCF growth (stage 1)
- 8.00%
- DCF terminal growth
- 3.00%
- DCF forecast years
- 5
- DDM dividend growth
- 3.00%
Tune these per company in the Hajras Odoo backend; values recompute automatically.
Wealth simulator
What if you'd invested in Avalon Pharma regularly?
Starting year
- Invested
- 1K/yr · 1K total(2026 → today · 1 yrs)
- your value today is
- 1K SAR
- Total return
- +2.2%(+2.2% Dividends · 0.0% Capital gain)
- Annualised (IRR)
- +4.9%
Invested1KSAR
Dividends22SAR
Capital gain0SAR
InvestedCapital gainDividendstap a bar for figures
Community Notes0
No notes yet. Be the first to share a thesis.